GenSight Biologics finalizes its €1.7 million fundraising round

GenSight Biologics has confirmed the settlement of its recent €1,694,715.5256 capital increase. This transaction resulted in the issuance of 14,153,928 ordinary shares, which have been trading on Euronext Paris since March 12, 2026. In addition, 4,270,464 pre-funded share warrants were offered, along with 18,424,392 share warrants for investors. These warrants entitle holders to subscribe to an additional 4,270,464 and 9,212,196 shares, respectively.

GenSight Biologics specializes in gene therapies for treating neurodegenerative diseases. The company's risk factors are detailed in its registration documents. The company's approach is based on innovative technologies to restore vision in patients with retinal diseases.